The ADCK2 Knockout A-549 Polyclonal Cells product comprises a heterogeneous population of A-549 lung adenocarcinoma epithelial cells edited by CRISPR/Cas9 to disrupt the ADCK2 gene. This polyclonal knockout pool is delivered as a ready-to-use culture, enabling researchers to interrogate the loss of ADCK2 function without the need for single-cell cloning. The CRISPR/Cas9-mediated gene disruption introduces targeted loss-of-function mutations across the cell population, generating a versatile tool for studying mitochondrial biology, coenzyme Q metabolism, and oxidative phosphorylation. The polyclonal format captures the diversity of editing events, making it suitable for pooled functional assays and robust phenotypic screening in a cancer-relevant background.
The host A-549 cell line originates from human lung carcinoma tissue of a 58-year-old male and exhibits an adherent, epithelial morphology. Widely employed as a model for non-small-cell lung cancer, A-549 cells recapitulate key aspects of pulmonary drug metabolism, viral infection susceptibility, and oncogenic signaling. Their well-characterized mitochondrial network and metabolic plasticity provide an appropriate context in which to dissect the consequences of ADCK2 loss, particularly given the gene’s role in mitochondrial ubiquinone biosynthesis. The combination of a lung adenocarcinoma background with ADCK2 knockout creates a clinically pertinent system for investigating metabolic vulnerabilities in cancer cells.
ADCK2 encodes a mitochondrial atypical kinase that is integral to the coenzyme Q biosynthetic pathway, where it facilitates efficient ubiquinone production and supports electron transport chain function. ADCK2 is transcriptionally regulated by PPARGC1A and is responsive to mitochondrial stress signals and AMPK-mediated energy sensing. It functions upstream of several biosynthetic enzymes, notably COQ3, COQ5, and COQ7, and physically interacts with COQ8A, COQ8B, and COQ10 within the coenzyme Q complex. Disruption of ADCK2 impairs this biosynthetic cascade, leading to diminished coenzyme Q10 levels, respiratory chain defects, and elevated oxidative stress??a mechanistic framework extensively validated in studies of primary coenzyme Q10 deficiency and syndromic mitochondrial disorders.
In the A-549 background, ADCK2 knockout assumes particular significance due to the interplay between mitochondrial dysfunction and cancer metabolism. Lung adenocarcinoma cells rely on robust mitochondrial respiration and redox homeostasis for proliferation and survival; loss of ADCK2 perturbs these processes, potentially sensitizing cells to oxidative damage or metabolic stress. This model therefore connects the fundamental biology of coenzyme Q biosynthesis with translational questions in oncology, allowing investigation of how defects in ubiquinone metabolism influence tumor cell fitness, drug responses, and adaptation to the tumor microenvironment.
Typical research applications span mitochondrial disease modeling, cancer metabolism studies, and drug screening. Investigators commonly employ western blotting to assess COQ protein expression, RT-qPCR to quantify transcripts of coenzyme Q biosynthesis genes, and Seahorse analyses to measure mitochondrial respiration. Direct quantification of coenzyme Q10 by HPLC, ATP measurements, and ROS detection assays provide complementary functional readouts. Immunofluorescence microscopy can reveal alterations in mitochondrial morphology, while apoptosis assays help link metabolic failure to cell death. These approaches support studies of oxidative stress, respiratory chain dysfunction, and the discovery of compounds targeting mitochondrial vulnerabilities. For further information on this product, please contact Ascent Research.
